ANGELA LYKE: Open Payments
NPI 1174295083 · VINCENNES, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$959 in 60 payments from 12 companies in 2025. Trend: 2023 $140 · 2024 $189 · 2025 $959
Food & beverage: $827Education: $131
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $233 |
| Axsome Therapeutics, Inc. | 4 | $190 |
| Vanda Pharmaceuticals Inc. | 14 | $183 |
| Janssen Pharmaceuticals, Inc | 20 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Biogen, Inc. | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Indivior Inc. | 1 | $20 |
Products named: Auvelity, FANAPT, INVEGA SUSTENNA, UZEDY, AUSTEDO XR, CAPLYTA, ZURZUVAE, INGREZZA.
Industry payments across IN — which companies pay providers there.
